Mohana Giruparajah1, Jackie Bosch2, Thomas Vanassche1, Katie Mattina1, Stuart J Connolly3, Calin Pater4, Robert G Hart5. 1. Population Health Research Institute, Hamilton, Ontario, Canada. 2. Population Health Research Institute, School of Rehabilitation Sciences, McMaster University, Hamilton, Ontario, Canada. 3. Population Health Research Institute, Department of Medicine (Cardiology), McMaster University, Hamilton, Ontario, Canada. 4. Bayer Healthcare, Leverkusen, Germany. 5. Population Health Research Institute, Department of Medicine (Neurology), McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: About 25% of ischemic strokes are categorized as cryptogenic (i.e. of unknown cause), but few data exist about the extent of diagnostic testing or treatment. We undertook an international survey to characterize current diagnostic evaluation and antithrombotic management of patients with cryptogenic ischemic stroke in 2014. AIMS/HYPOTHESIS: To determine the type of diagnostic evaluation undertaken for cryptogenic ischemic stroke and antithrombotic management and to compare across global regions. METHODS: An 18-question online survey was sent to 995 physicians involved in stroke care in 61 countries. Countries were separated into World Bank global regions and income groups. Diagnostic tests were considered routine if performed in >75% of patients at a center. RESULTS: Three hundred one completed surveys were received from 48 countries (response rate ∼30%). The majority (82%) of hospitals were from high-income countries and mainly from Europe and Central Asia (56%) and North America (19%). For ischemic stroke patients, magnetic resonance imaging is routinely obtained at 36% of hospitals (highest in North America, 58%). Among cryptogenic stroke patients, transesophageal echocardiography is routinely performed in 17% of hospitals. More than 24 hour cardiac rhythm monitoring is done routinely at relatively few (17%) hospitals (highest in North America, 33%). Intracranial arterial imaging is done routinely at 70% of hospitals, with no significant regional differences. Antiplatelet therapies are routinely prescribed for secondary prevention at 94% of hospitals. CONCLUSIONS: Based on self-selected respondents from a large number of international stroke centers, transesophageal echocardiography and prolonged (>24 h) cardiac rhythm monitoring are not routinely performed in cryptogenic stroke patients, even in high-income countries. Antiplatelet therapy is the global standard for secondary prevention of cryptogenic stroke.
BACKGROUND: About 25% of ischemic strokes are categorized as cryptogenic (i.e. of unknown cause), but few data exist about the extent of diagnostic testing or treatment. We undertook an international survey to characterize current diagnostic evaluation and antithrombotic management of patients with cryptogenic ischemic stroke in 2014. AIMS/HYPOTHESIS: To determine the type of diagnostic evaluation undertaken for cryptogenic ischemic stroke and antithrombotic management and to compare across global regions. METHODS: An 18-question online survey was sent to 995 physicians involved in stroke care in 61 countries. Countries were separated into World Bank global regions and income groups. Diagnostic tests were considered routine if performed in >75% of patients at a center. RESULTS: Three hundred one completed surveys were received from 48 countries (response rate ∼30%). The majority (82%) of hospitals were from high-income countries and mainly from Europe and Central Asia (56%) and North America (19%). For ischemic strokepatients, magnetic resonance imaging is routinely obtained at 36% of hospitals (highest in North America, 58%). Among cryptogenic strokepatients, transesophageal echocardiography is routinely performed in 17% of hospitals. More than 24 hour cardiac rhythm monitoring is done routinely at relatively few (17%) hospitals (highest in North America, 33%). Intracranial arterial imaging is done routinely at 70% of hospitals, with no significant regional differences. Antiplatelet therapies are routinely prescribed for secondary prevention at 94% of hospitals. CONCLUSIONS: Based on self-selected respondents from a large number of international stroke centers, transesophageal echocardiography and prolonged (>24 h) cardiac rhythm monitoring are not routinely performed in cryptogenic strokepatients, even in high-income countries. Antiplatelet therapy is the global standard for secondary prevention of cryptogenic stroke.
Authors: Jiann-Der Lee; Ya-Wen Kuo; Chuan-Pin Lee; Yen-Chu Huang; Meng Lee; Tsong-Hai Lee Journal: Int J Environ Res Public Health Date: 2022-06-14 Impact factor: 4.614
Authors: Robert G Hart; Mukul Sharma; Hardi Mundl; Ashkan Shoamanesh; Scott E Kasner; Scott D Berkowitz; Guillaume Pare; Bodo Kirsch; Janice Pogue; Calin Pater; Gary Peters; Antoni Davalos; Wilfried Lang; Yongjun Wang; Yilong Wang; Luis Cunha; Jens Eckstein; Turgut Tatlisumak; Nikolay Shamalov; Robert Mikulik; Pablo Lavados; Graeme J Hankey; Anna Czlonkowska; Danilo Toni; Sebastian F Ameriso; Rubens J Gagliardi; Pierre Amarenco; Daniel Bereczki; Shinichiro Uchiyama; Arne Lindgren; Matthias Endres; Raf Brouns; Byung-Woo Yoon; George Ntaios; Roland Veltkamp; Keith W Muir; Serefnur Ozturk; Antonio Arauz; Natan Bornstein; Alan Bryer; Martin J O'Donnell; Jeffrey Weitz; Frank Peacock; Ellison Themeles; Stuart J Connolly Journal: Eur Stroke J Date: 2016-08-03
Authors: Valeria Guglielmi; Leon A Rinkel; Nina-Suzanne Groeneveld; Nick Hj Lobé; S Matthijs Boekholdt; Berto J Bouma; Ludo Fm Beenen; Henk A Marquering; Charles Blm Majoie; Yvo Bwem Roos; Adrienne van Randen; R Nils Planken; Jonathan M Coutinho Journal: Eur Stroke J Date: 2020-10-11
Authors: Samuel S Bruce; Babak B Navi; Cenai Zhang; Jiwon Kim; Richard B Devereux; Edward J Schenck; Art Sedrakyan; Iván Díaz; Hooman Kamel Journal: BMJ Surg Interv Health Technol Date: 2022-02-07
Authors: Yan Xu; Ashkan Shoamanesh; Sam Schulman; Dar Dowlatshahi; Rustam Al-Shahi Salman; Ioana Doina Moldovan; Philip Stephen Wells; Fahad AlKherayf Journal: PLoS One Date: 2018-01-25 Impact factor: 3.240